Human Epidermal and Monocyte-Derived Langerhans Cells Express Functional P2X7 Receptors  by Georgiou, Jennifer G. et al.
Human Epidermal and Monocyte-Derived Langerhans Cells
Express Functional P2X7 Receptors
Jennifer G. Georgiou, Kristen K. Skarratt, Stephen J. Fuller, Christopher J. Martin,w Richard I.
Christopherson,z James S. Wiley, and Ronald Sluyter
Departments of Medicine and wSurgery, University of Sydney at Nepean Hospital, Penrith, NSW, Australia; zSchool of Molecular and Microbial Biosciences,
University of Sydney, Sydney, NSW, Australia
Monocyte-derived dendritic cells (Mo-DC) express functional P2X7 receptors; however, the expression of these
receptors on tissue-derived dendritic cells including epidermal Langerhans cells (LC) is unknown. Using immuno-
labeling and ﬂow cytometry, we demonstrated that P2X7 was present on both human epidermal LC and monocyte-
derived LC (Mo-LC), as well as on human keratinocytes. The ecto-ATPDase (CD39) was also present on LC, but not
keratinocytes. The P2X7 agonists, 2
0- and 30-0(4-benzoylbenzoyl) adenosine 50-triphosphate (BzATP) or ATP, but
neither adenosine 50-diphosphate (ADP) nor uridine 50-triphosphate (UTP), induced ethidiumþ uptake into these
cells. Furthermore, ATP-induced ethidiumþ uptake into epidermal LC, Mo-LC and keratinocytes was inhibited by
the specific P2X7 antagonist, KN-62 (1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine).
ATP-induced ethidiumþ uptake into Mo-LC and Mo-DC was 2- and 3-fold greater, respectively, than that for fresh
monocytes. P2X7 activation on LC induced downstream signaling events, as BzATP or ATP, but neither ADP nor
UTP, induced shedding of the low-afﬁnity receptor for IgE (CD23) from Mo-LC. This process was inhibited by KN-62.
Finally, ATP-induced ethidiumþ uptake and CD23 shedding were impaired in Mo-LC obtained from subjects ho-
mozygous for the loss-of-function Glu-496 to Ala polymorphism in the P2X7 receptor. These results demonstrate
that human LC express functional P2X7 receptors, and suggest a role for this receptor in the skin immune system.
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Purinergic receptors are classified into either P1 receptors,
selective for adenosine, or P2 receptors, selective for
adenosine 50-triphosphate (ATP) and adenosine 50-diphos-
phate (ADP), which are subdivided into P2X and P2Y re-
ceptors (Ralevic and Burnstock, 1998). Extracellular
nucleotides have attracted considerable interest as impor-
tant signaling molecules in relation to both dendritic cells
(DC) (la Sala et al, 2003) and the skin immune system
(Granstein, 2002; Holzer and Granstein, 2004). DC are cen-
tral in the initiation of adaptive immune responses and there
is considerable interest in understanding the factors that
govern the various stages of DC migration, maturation, and
activation (Cavanagh and Von Andrian, 2002). Epidermal
Langerhans cells (LC) are a subtype of DC located within
the epidermis where they play an important role in the skin
immune system (Romani et al, 2003); however, the expres-
sion and function of purinergic receptors on epidermal LC
remain unknown.
P2X receptors are ligand-gated cation channels with
identical subunits assembled in a trimeric structure each
with two transmembrane domains containing intracellular
amino and carboxyl termini (North, 2002). Activation of P2X7
by 20- and 30-0(4-benzoylbenzoyl) ATP (BzATP) or ATP
opens a cation-selective channel allowing an influx of Ca2þ
and ethidiumþ , and an efflux of Kþ (Surprenant et al, 1996;
Gargett et al, 1997). P2X7 receptor function varies consid-
erably between subjects (Lammas et al, 1997; Gu et al,
2000), explained in part by loss-of-function polymorphisms
(Gu et al, 2001, 2004; Wiley et al, 2003; Skarratt et al, 2005).
P2X7 is predominantly expressed on cells from the hem-
atopoietic lineages for erythrocytes, T and B lymphocytes,
NK cells, monocytes, and macrophages (Hickman et al,
1994; Gu et al, 2000; Sluyter et al, 2004b). In addition, P2X7
has been identified on monocyte-derived dendritic cells
(Mo-DC) where it plays a role in antigen presentation (Mutini
et al, 1999), apoptosis (Coutinho-Silva et al, 1999), cytokine
release (Ferrari et al, 2000), and the shedding of CD23
(Sluyter and Wiley, 2002). ATP can also permeabilize human
epidermal LC via a molecule that may be P2X7 (Girolomoni
et al, 1993); however, this study preceded the cloning of the
P2X7 gene, and the development of anti-P2X7 antibodies
and P2X7 antagonists, and thus a specific role for P2X7
was not established. We have used flow cytometric and
Abbreviations: ADP, adenosine 50-diphosphate; ATP, adenosine 50-
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benzoylbenzoyl) ATP; DC, dendritic cells; DMSO, dimethyl sulfox-
ide; EC, epidermal cells; FITC, fluorescein isothiocyanate; GM-
CSF, granulocyte macrophage-colony stimulating factor; HEPES,
4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid; IL, interleukin;
LC, Langerhans cells; mAb, monoclonal antibody; MFI, mean flu-
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pharmacological approaches to investigate whether human
LC express functional P2X7 receptors.
Results
Human epidermal Langerhans cells and keratinocytes
express P2X7 To determine whether epidermal LC express
P2X7, epidermal cell (EC) suspensions were prepared from
freshly excised human skin, labeled with mAb, and exam-
ined by flow cytometry. CD1aþ EC (epidermal LC) were
found to express P2X7 on the cell surface with a mean flu-
orescence intensity (MFI) of 21.9  17.1 (n¼5), as well as
cell surface CD39 (MFI of 538.1  248.1, n¼5) (Fig 1). It
was noted that P2X7 was also present on CD1a
 EC, which
predominantly consist of keratinocytes, and that expressed
P2X7 with an MFI of 49.3  29.5 (n¼5), but were negative
for CD39 (Fig 1).
P2X7 agonists induce ethidium
þ uptake into epidermal
Langerhans cells and keratinocytes The effect of various
extracellular nucleotides on ethidiumþ uptake into CD1aþ
EC was then studied. Uptake of ethidiumþ in the absence
of nucleotide was minimal (Fig 2). The P2X7 agonists, 200
mM BzATP and 1 mM ATP, induced the uptake of ethidiumþ
with an MFI of 483.5  259.0 and 357.1  214.1, respec-
tively (n¼6; Fig 2). In contrast, 1 mM ADP and 1 mM uridine
50-triphosphate (UTP) failed to induce ethidiumþ uptake
(MFI of 1.6  2.8 and 1.6  2.6, respectively, n¼3; Fig 2)
with values similar to the uptake of ethidiumþ in the ab-
sence of nucleotide.
Similar results were also observed with CD1a EC
(keratinocytes). BzATP and ATP induced the uptake of
ethidiumþ with an MFI of 1154.6  621.8 and 1014.8 
454.9, respectively (n¼6; Fig 2), whereas ADP and UTP
failed to induce ethidiumþ uptake with an MFI of 1.8  1.6
and 1.3  2.2, respectively (n¼3; Fig 2). Of note, both BzATP-
and ATP-induced uptake of ethidiumþ into keratinocytes
Figure 1
Expression of P2X7 receptors and CD39 on epidermal Langerhans
cells. Epidermal cells (EC) were labeled with fluorescein isothiocyanate
(FITC)-P2X7 (solid line) or FITC-isotype control (dotted line) monoclonal
antibody (mAb), phycoerythrin (PE)-CD1a mAb and 7-amino-
actinomycin (7AAD), or PE-CD39 (solid line) or PE-isotype control (dot-
ted line) mAb, FITC-CD1a mAb and 7AAD, and analyzed by flow
cytometry gating on CD1aþ7AAD EC (Langerhans cells) and
CD1a7AAD EC (keratinocytes). Results are representative of five
experiments.
Figure2
P2X7 agonists induce ethidium
þ uptake into epidermal La-
ngerhans cells (LC) and keratinocytes. Epidermal cells (EC) in KCl
medium containing 25 mM ethidiumþ were incubated in the absence
(basal) or presence of 1 mM ATP (adenosine 50-triphosphate), 200 mM
BzATP (20- and 30-0(4-benzoylbenzoyl) ATP), 1 mM ADP (adenosine 50-
diphosphate), or 1 mM UTP (uridine 50-triphosphate) at 371C for 5 min.
Incubations were stopped by the addition of MgCl2 medium followed
by centrifugation. The EC were labeled with fluorescein isothiocyanate-
CD1a mAb and analyzed by flow cytometry gating on CD1aþ EC (LC)
and CD1a EC (keratinocytes). Results are representative of six (basal,
ATP, and BzATP) or three (ADP and UTP) experiments.
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was significantly greater than that into epidermal LC
(po0.05 and po0.01, respectively).
P2X7 antagonist impairs ATP-induced ethidium
þ uptake
into epidermal Langerhans cells and keratinocytes To
examine a role for P2X7 in the ATP-induced ethidium
þ up-
take, EC were pre-incubated with the specific P2X7 antag-
onist, KN-62 (1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-
tyrosyl]-4-phenylpiperazine) (Gargett and Wiley, 1997), at
either 1 or 10 mM or an equal volume of dimethyl sulfoxide
(DMSO) vehicle, before incubation with ATP at a concen-
tration of 100 mM, which is close to the EC50 (  85 mM) for
recombinant and native P2X7 (Surprenant et al, 1996; Gar-
gett et al, 1997). KN-62 at either concentration completely
inhibited the ATP-induced ethidiumþ uptake into CD1aþ
EC isolated from three different subjects (Table I). Similarly,
KN-62 at 10 or 1 mM significantly inhibited ATP-induced eth-
idiumþ uptake into CD1a EC from these same three sub-
jects by over 98% or 90%, respectively (Table I). Ethidiumþ
uptake in the absence of ATP was similar in EC incubated
with KN-62 or DMSO vehicle (results not shown).
Monocyte-derived Langerhans cells (Mo-LC) express
P2X7 To further study the expression and function of P2X7
on LC, Mo-LC were generated using a standard protocol
(Geissmann et al, 2002). The identity of the Mo-LC was
confirmed by expression of the LC markers, CD1a, E-cad-
herin, and CD207 (Langerin), as well as the DC markers,
CD11c and HLA-DR, low to medium levels of the co-
stimulatory molecules, CD40, CD80, and CD86, and near-
to-absent levels of both the DC maturation marker, CD83
and the monocyte/macrophage marker, CD14 (Fig S1; Table
S1). Importantly, as observed with epidermal LC, Mo-LC
expressed P2X7 (MFI of 10.5  6.6, n¼19), as well as CD39
(MFI of 51.1  24.9, n¼19) (Fig 3).
P2X7 agonists induce ethidium
þ uptake into Mo-LC The
effect of various extracellular nucleotides on ethidiumþ up-
take into Mo-LC was then studied. Both 200 mM BzATP and
1 mM ATP induced the uptake of ethidiumþ with mean ar-
bitrary units of ethidiumþ uptake of 7652  634 and
5630  1223, respectively (n¼3; Fig 4). As for epidermal
LC, 1 mM ADP, and 1 mM UTP failed to induce ethidiumþ
uptake with mean arbitrary units of ethidiumþ uptake of
47  43 and 38  52, respectively (n¼3; Fig 4).
P2X7 antagonist impairs ATP-induced ethidium
þ uptake
into Mo-LC To confirm a role for P2X7 in ATP-induced up-
take of ethidiumþ into Mo-LC, cells were pre-incubated
with KN-62 or an equal volume of DMSO vehicle, followed
by incubation with 100 mM ATP. Similar to epidermal LC,
KN-62 at a concentration of either 1 or 10 mM significantly
inhibited the ATP-induced ethidiumþ uptake into Mo-LC by
85.6  6.0% and 98.1  3.3% respectively (n¼3, po0.01;
Fig 5). Ethidiumþ uptake in the absence of ATP was similar
in Mo-LC incubated with KN-62 or DMSO vehicle (results
not shown).
ATP-induced ethidiumþ uptake is impaired in Mo-LC
homozygous for the Glu496Ala polymorphism Mo-LC
offer the unique advantage in that these cells can be readily
generated from subjects with known loss-of-function poly-
morphisms in P2X7 such as the Glu
496Ala polymorphism
(Gu et al, 2001). Therefore, Mo-LC were generated in paired
experiments from subjects who were either wild-type or
homozygous for the Glu496Ala polymorphism, and both
P2X7 expression and function were examined. Using a small
panel of phenotypic markers, there was no difference in the
level of expression of either CD1a, CD39, CD83, CD207, or
E-cadherin on Mo-LC between genotypes (results not
Table I. P2X7 antagonist inhibits ATP-induced ethidium
þ uptake into epidermal LC and keratinocytes
ATP-induced ethidiumþ uptake (MFI)a
Epidermal LC Keratinocytes
DMSO 118.6  45.9 543.5  94.9
1 mM KN-62 0  0 po0.02b 39.5  13.8 po0.01b
10 mM KN-62 0  0 po0.02b 6.0  2.3 po0.01b
aEC in KCl medium were pre-incubated with DMSO vehicle, 1 mM KN-62 or 10 mM KN-62 at 371C for 15 min, before incubation with 25 mM ethidiumþ
in the absence or presence of 100 mM ATP at 371C for 5 min. Incubations were stopped by the addition of MgCl2 medium followed by centrifugation. EC
were labeled with FITC-CD1a mAb and analyzed by flow cytometry gating on CD1aþ EC (epidermal LC) or CD1a EC (keratinocytes). The level of ATP-
induced ethidiumþ uptake was determined as the difference in MFI of cell-associated ethidiumþ of cells incubated in the presence and absence of ATP.
Results are the mean  SD of three experiments.
bTo corresponding DMSO vehicle control.
ATP, adenosine 50-triphosphate; EC, epidermal cells; LC, Langerhans cells; DMSO, dimethyl sulfoxide; KN-62, 1-[N,O-bis(5-isoquinolinesulphonyl)-N-
methyl-L-tyrosyl]-4-phenylpiperazine; FITC, fluorescein isothiocyanate; mAb, monoclonal antibody; MFI, mean fluorescence intensity
Figure3
Expression of P2X7 receptors and CD39 on monocyte-derived La-
ngerhans cells (Mo-LC). Mo-LC were labeled with fluorescein is-
othiocyanate (FITC)-P2X7 (solid line) or FITC-isotype control (dotted
line) monoclonal antibody (mAb), or phycoerythrin (PE)-CD39 (solid line)
or PE-isotype control (dotted line) mAb and analyzed by flow cytometry.
Results are representative of 19 experiments.
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shown). In contrast, P2X7 expression was lower on ho-
mozygous Mo-LC than on wild-type Mo-LC (MFI of
4.6  8.0 vs 15.1  4.0, n¼3), although this failed to reach
significance (p¼ 0.11). A more striking difference was seen
in P2X7 function since ATP-induced ethidium
þ uptake was
near to absent in homozygous Mo-LC and significant-
ly lower when compared with wild-type Mo-LC (mean
arbitrary units of ethidiumþ uptake of 34  59 vs
13906  5518, respectively, n¼3, po0.02; Fig 6).
P2X7 function in Mo-LC and Mo-DC, and monocytes
P2X7 function increases as monocytes differentiate into
macrophages (Hickman et al, 1994); however, it has not
been reported whether a similar phenomenon occurs as
monocytes differentiate into LC or DC. Therefore, to exam-
ine this and to compare the relative levels of P2X7 function
between these two DC subtypes, Mo-LC and Mo-DC were
generated in paired experiments, and the ATP-induced et-
hidiumþ uptake was examined in these cells obtained at
day 6, as well as in monocytes present in the peripheral
blood mononuclear cell preparations obtained on day 0.
ATP induced the uptake of ethidiumþ into Mo-DC (mean
arbitrary units of uptake of 15148  5149, n¼ 3), which was
on average 2-fold higher than that into Mo-LC (mean arbi-
trary units of uptake of 8316  3764, n¼3) (Fig 7). ATP also
induced the uptake of ethidiumþ into monocytes (mean
arbitrary units of uptake of 4759  1543, n¼3; Fig 7); how-
ever, this was at levels lower than that observed in Mo-LC
and Mo-DC, and in the latter case reaching statistical sig-
nificance (po0.03).
In these paired experiments, the level of P2X7 and CD39
expression on Mo-LC and Mo-DC was also examined. Mo-
LC and Mo-DC expressed similar levels of P2X7 on the cell
Figure 4
P2X7 agonists induce ethidium
þ uptake into monocyte-derived
Langerhans cells (Mo-LC). Epidermal cells were labeled with fluo-
rescein isothiocyanate (FITC)-CD1a monoclonal antibody and sus-
pended in KCl medium at 371C. Ethidiumþ (25 mM) was added,
followed 40 s later by the addition of nucleotide (arrow). The mean
channel of cell-associated fluorescence was measured by time-re-
solved flow cytometry for Mo-LC incubated in the absence (; basal) or
presence of 1 mM ATP (adenosine 50-triphosphate) (), 200 mM BzATP
(20- and 30-0(4-benzoylbenzoyl) ATP) (m), 1 mM ADP (adenosine 50-
diphosphate) (’), or 1 mM UTP (uridine 50-triphosphate) (E). Results
are representative of three experiments.
Figure 5
P2X7 antagonist inhibits adenosine 5
0-triphosphate (ATP)-induced
ethidiumþ uptake into monocyte-derived Langerhans cells (Mo-
LC). Mo-LC were labeled with fluorescein isothiocyanate (FITC)-CD1a
mAb and suspended in KCl medium at 371C. Mo-LC were pre-incu-
bated with dimethyl sulfoxide vehicle (), 1 mM KN-62 (1-[N,O-bis(5-
isoquinolinesulphonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine) (m), or
10 mM KN-62 (’) at 371C for 15 min; then, 25 mM ethidiumþ was
added, followed 40 s later by the addition of 100 mM ATP (arrow). The
mean channel of cell-associated fluorescence was measured by time-
resolved flow cytometry for Mo-LC incubated in the absence (; basal)
or presence of ATP (,m,’). Results are representative of three
experiments.
Figure6
Glu496Ala polymorphism impairs adenosine 50-triphosphate (ATP)-
induced ethidiumþ uptake into monocyte-derived Langerhans
cells (Mo-LC). Mo-LC from a subjects either wild-type at 496 (,)
or homozygous for the Glu496Ala (E496A) polymorphism (m) were labe-
led with fluorescein isothiocyanate (FITC)-CD1a monoclonial antibody
and suspended in KCl medium at 371C. Ethidiumþ (25 mM) was added,
followed 40 s later by the addition of 1 mM ATP (arrow). The mean
channel of cell-associated fluorescence was measured by time-re-
solved flow cytometry for Mo-LC incubated in the absence (; basal) or
presence (, m) of ATP. Results are representative of three experi-
ments.
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surface (MFI of 12.8  3.5 and 15.2  0.4, respectively,
n¼3; Fig 8). In contrast, the level of CD39 expressed on
Mo-LC was 3-fold greater than that on Mo-DC (MFI of
66.4  23.7 vs 24.8  15.0, respectively, n¼3; Fig 8), al-
though this failed to reach statistical significance (p¼ 0.06).
ATP induces CD23 shedding from Mo-LC via P2X7 ac-
tivation Untreated Mo-LC were found to express CD23
(51.1  30.0 MFI, n¼ 3; Fig 9). Therefore, to determine
whether activation of P2X7 can also cause downstream
signaling events in Mo-LC, the effect of ATP on CD23
shedding was examined as previously described for B
lymphocytes (Gu et al, 1998) and Mo-DC (Sluyter and Wiley,
2002). CD23 expression on Mo-LC incubated in the ab-
sence of nucleotide (Fig 9) was similar to that of untreated
cells and was used to determine the percentage loss of
CD23 in the presence of nucleotide. Incubation of Mo-LC
with either 200 mM BzATP or 1 mM ATP for 5 min induced a
near-complete loss of CD23 from these cells (mean loss of
CD23 of 87.1  10.5% and 87.6  10.3%, respectively,
n¼5; Fig 9). In contrast, 1 mM ADP and 1 mM UTP had a
minimal effect (mean loss of CD23 of 10.6  9.4% and
4.1  4.1%, respectively, n¼ 5; Fig 9).
To confirm a role for P2X7 in the ATP-induced shedding
of CD23 from wild-type Mo-LC, cells were pre-incubated
with KN-62 or an equal volume of DMSO vehicle before
incubation with 100 mM ATP. KN-62 at concentrations of
either 1 or 10 mM inhibited the ATP-induced shedding of
CD23 from Mo-LC by 64.4  36.4% and 88.0  20.8%, re-
spectively (n¼ 3); however, only the latter reached statistical
significance (po0.02).
The ability of ATP to induce shedding of CD23 from the
surface of Mo-LC was also compared using Mo-LC gener-
ated from subjects who were wild-type or homozygous for
the Glu496Ala polymorphism. Similar to the other phenotypic
markers (above), the initial level of CD23 on Mo-LC of either
Figure 7
Adenosine 50-triphosphate (ATP) induced ethidiumþ uptake into
monocyte-derived Langerhans cells (Mo-LC), monocyte-derived
dendritic cells (Mo-DC), and monocytes. Day 6 Mo-LC (,) and
Mo-DC (m) were labeled with fluorescein isothiocyanate (FITC)-CD1a
monoclonal antibody (mAb), and day 0 monocytes (’) were labeled
with FITC-CD14 mAb, and suspended in KCl medium at 371C. Et-
hidiumþ (25 mM) was added, followed 40 s later by the addition of 1
mM ATP (arrow). The mean channel of cell-associated fluorescence
was measured by time-resolved flow cytometry for cells incubated in
the absence (; basal) or presence of ATP (,m,’). Results are rep-
resentative of three experiments.
Figure 8
Expression of P2X7 receptors and CD39 on monocyte-derived La-
ngerhans cells (Mo-LC) and monocyte-derived dendritic cells (Mo-
DC). Mo-LC (solid and dotted lines) and Mo-DC (shaded line) were
generated in paired experiments and labeled with fluorescein is-
othiocyanate (FITC)-P2X7 (solid and shaded lines) or FITC-isotype con-
trol (dotted line) monoclonal antibody (mAb), or phycoerythrin (PE)-
CD39 (solid and shaded lines) or PE-isotype control (dotted line) mAb
and analyzed by flow cytometry. For clarity, only isotype control mAb
labeling on Mo-LC is shown. Results are representative of three
experiments.
Figure9
P2X7 agonists induce CD23 shedding from monocyte-derived La-
ngerhans cells (Mo-LC). Mo-LC in KCl medium were incubated in the
absence (control) or presence of 1 mM ATP (adenosine 50-tripho-
sphate), 200 mM BzATP (20- and 30-0(4-benzoylbenzoyl) ATP), 1 mM
ADP (adenosine 50-diphosphate), or 1 mM UTP (uridine 50-triphosphate)
at 371C for 5 min. Incubations were stopped by the addition of MgCl2
medium followed by centrifugation. Untreated or treated Mo-LC were
labeled with phycoerythrin (PE)-CD23 (solid line) or PE-isotype control
(dotted line) monoclonal antibody (mAb) and analyzed by flow cytome-
try. Results are representative of five experiments.
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genotype was similar (results not shown). In paired exper-
iments, ATP-induced shedding of CD23 was significantly
lower from homozygous Mo-LC than from wild-type Mo-LC
(mean loss of CD23 of 47.8  5.0% vs 86.1  6.1%, re-
spectively, n¼3, po0.01).
Discussion
The main finding of this study is that human epidermal LC
and Mo-LC both express functional P2X7 receptors. Using
an anti-P2X7 mAb and flow cytometry, we demonstrated
that P2X7 was present on the surface of LC and that ATP
induced the uptake of ethidiumþ into these cells. Several
observations demonstrate that P2X7 is responsible for this
ethidiumþ uptake. First, the P2X7 agonists BzATP and ATP,
but not ADP or UTP (agonists of other P2X and P2Y re-
ceptors), induced ethidiumþ uptake into LC. Moreover, 200
mM BzATP, a full agonist for the P2X7 receptor (Gargett et al,
1997), consistently induced higher levels of ethidiumþ
uptake than 1 mM ATP, which is a partial P2X7 agonist.
Second, the specific P2X7 antagonist, KN-62, inhibited the
ATP-induced ethidiumþ uptake into LC. Third, ATP-induced
ethidiumþ uptake was impaired in Mo-LC homozygous for
the loss-of-function Glu496Ala polymorphism.
Few studies have determined whether P2X7 is present on
tissue-derived DC. Anti-P2X7 mAb labeled DC-like cells in
human tonsil (Buell et al, 1998) and freshly isolated murine
splenic DC express a receptor with functional characteris-
tics of P2X7 (Nihei et al, 2000), while ATP can induce uptake
of Lucifer Yellow into murine fetal skin-derived DC (Mutini
et al, 1999) and murine epidermal LC (Mizumoto et al, 2002).
Moreover, ATP can permeabilize human epidermal LC as
assessed by propidium2þ uptake via a process character-
istic of P2X7 activation (Girolomoni et al, 1993). These LC,
however, were relatively resistant to the permeabilizing ef-
fect of ATP, due to membrane ATPDase activity, with less
than 5% of LC positive for propidium2þ uptake after 5 min
incubation with 10 mM ATP or after a 30-min incubation with
1 mM ATP. In contrast, in our study 1 mM ATP induced the
uptake of ethidiumþ into  55% of LC within 5 min. This
difference is most likely due to differences in the incubation
media and the fluorescent cations used. The previous study
incubated LC in serum-free DMEM culture media, whereas
our study used a KCl medium that is nominally free of ex-
tracellular Naþ , Ca2þ , and Mg2þ . These cations are all
standard constituents of culture media but are known to
inhibit P2X7 function by binding to an unidentified inhibitory
site on the receptor (Wiley et al, 1992; Michel et al, 1999) or
by reducing the availability of the ATP4- species required for
P2X7 activation (North, 2002). In addition, the presence of
Ca2þ and Mg2þ in the culture medium may have enhanced
the cation-dependent ATPDase activity of CD39 (Wang and
Guidotti, 1996), thus reducing the half-life of extracellular
ATP. Differences in permeability have also been reported for
ethidiumþ and propidium2þ . P2X7 pore formation allows
uptake of cations up to the size of ethidiumþ (314 Da) and
YoPRO-1þ (375 Da) but not propidium2þ (415 Da) (Wiley
et al, 1993; Chused et al, 1996), whereas ATP-induced up-
take of propidium2þ and the anion, Lucifer Yellow (457 Da),
occurs via non-selective pores (Steinberg et al, 1987) and
possibly represents an early event of P2X7-mediated
apoptosis.
The presence of P2X7 on human Mo-DC has been re-
ported by several groups (Berchtold et al, 1999; Coutinho-
Silva et al, 1999; Ferrari et al, 2000; Sluyter and Wiley, 2002).
Here, we demonstrate that functional P2X7 receptors are
also present on Mo-LC. Mo-LC have been used as a model
to study LC by others (Geissmann et al, 2002; Guironnet
et al, 2002; Mizuno et al, 2004) and phenotypic analysis of
the Mo-LC generated in this study resemble those previ-
ously described, expressing the LC markers CD1aþ , E-
cadherin, and CD207 (Langerin), as well as the DC markers
CD11c and HLA-DR. Moreover, our cultured Mo-LC ex-
pressed low to moderate levels of the activation markers,
CD40, CD80, CD83, and CD86, typical of immature LC
within the epidermis. This in vitro model allowed the gen-
eration of Mo-LC from subjects either wild-type or ho-
mozygous for the Glu496Ala polymorphism. ATP has been
shown to induce maturation of Mo-DC (Berchtold et al,
1999; Schnurr et al, 2000), a process thought to be medi-
ated by P2Y11 (Wilkin et al, 2001). Here, Mo-LC of either
genotype had a similar phenotype and thus it is unlikely that
P2X7 affects the differentiation or maturation of Mo-LC. The
expression of P2X7 on homozygous Mo-LC, however, was
lower than that on their wild-type counterparts. Although the
Glu496Ala polymorphism does not affect P2X7 expression
on lymphocytes (Gu et al, 2001), its expression on lip-
opolysaccharide-primed monocytes and on interferon-g-
activated macrophages generated from homozygous sub-
jects is also reduced (Saunders et al, 2003; Sluyter et al,
2004a), suggesting that this polymorphism may affect the
upregulation or retention of this receptor on the surface of
cells of monocyte lineage.
A direct comparison of ATP-induced ethidiumþ uptake
into epidermal LC and Mo-LC was not possible due to dif-
ferences in flow cytometer settings; however, the in vitro
model allowed a comparison of P2X7 function on Mo-LC,
Mo-DC, and monocytes. Comparison of ATP-induced et-
hidiumþ uptake demonstrated that P2X7 function was 2-
and 3-fold higher, respectively, on Mo-LC and Mo-DC com-
pared with monocytes, which parallels the many-fold up-
regulation of P2X7 function during monocyte to macrophage
differentiation (Hickman et al, 1994). Interestingly, P2X7
function was 2-fold higher on Mo-DC than on Mo-LC de-
spite a similar level of P2X7 expression between the two cell
types. In contrast, CD39 expression was 3-fold higher on
Mo-LC than on Mo-DC, suggesting that P2X7 function on
LC may in part be regulated by the ecto-ATPase, CD39.
Extracellular ATP also induced the shedding of the low-
affinity receptor for IgE, CD23, from Mo-LC via activation of
P2X7. BzATP and ATP, but neither ADP nor UTP, induced
CD23 shedding from Mo-LC, a process inhibited by KN-62
and impaired in Mo-LC homozygous for the loss-of-function
Glu496Ala polymorphism. An additional role for other P2X
receptors in the ATP-induced shedding of CD23 from Mo-
LC, however, cannot be excluded as this ATP-induced
shedding was not completely inhibited by KN-62 or in Mo-
LC homozygous for the Glu496Ala polymorphism, and that
mRNA for P2X1,4,5 is expressed in monocytes and Mo-DC
(Berchtold et al, 1999; Ferrari et al, 2000; Wang et al, 2004).
Nevertheless, given the potential role of CD23 in allergy and
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inflammation (Kijimoto-Ochiai, 2002), ATP-induced shed-
ding of CD23 from LC in the skin may have a role in health
and disease.
The ecto-ATPDase, CD39, was also found on epidermal
LC and Mo-LC but not on keratinocytes. The presence of
ATPDase activity on epidermal LC has been known for close
to 40 y (Wolf and Winkelmann, 1967) and has been used as
a phenotypic marker for these cells (Romani et al, 2003). But
not until recent studies using CD39 knockout mice was this
ATPDase activity identified as CD39 (Mizumoto et al, 2002).
In contrast, expression of CD39 on human LC is essentially
unknown. To the best of our knowledge, only one other
study has reported the expression of CD39 on CD1aþ LC in
the human epidermis (Davis et al, 1988), whereas CD39
mRNA has been identified in Mo-DC (Berchtold et al, 1999).
Although our study did not examine the activity of CD39 on
LC, the presence of CD39 on both epidermal and Mo-LC
supports the hypothesis that CD39 is the predominant AT-
PDase on human LC.
Functional P2X7 was also present on keratinocytes. As
for epidermal LC, anti-P2X7 mAb labeled these keratin-
ocytes, and BzATP and ATP, but neither ADP nor UTP, in-
duced ethidiumþ uptake into these cells, a process that
could be inhibited by KN-62. Immunohistochemistry and
functional studies have demonstrated the presence of P2X7
on rodent and human keratinocytes (Groschel-Stewart et al,
1999; Greig et al, 2003; Inoue et al, 2005), where it may play
a role in terminal differentiation and/or apoptosis (Greig
et al, 2003; Inoue et al, 2005). Moreover, ATP can perm-
eabilize human keratinocytes as assessed by propidium2þ
uptake via a molecule characteristic of P2X7 and to a level
greater than that observed for epidermal LC (Girolomoni
et al, 1993). Consistent with this observation, in our study,
the BzATP- and ATP-induced ethidiumþ uptake into kera-
tinocytes was also significantly greater than into epidermal
LC.
The functional significance of P2X7 on LC is unknown;
however, the studies with CD39 knockout mice support
multiple roles for extracellular ATP in the skin immune sys-
tem. Contact hypersensitivity (allergic contact dermatitis) is
attenuated in CD39 knockout mice, whereas chemically in-
duced cutaneous inflammation (irritant contact dermatitis) is
exacerbated in these mice possibly due to desensitization
of P2Y and activation of P2X receptors, respectively, as a
result of excessive amounts of extracellular ATP (Mizumoto
et al, 2002). Since ATP via P2X7 activation is known to in-
duce the release of pro-inflammatory cytokines such as in-
terleukin (IL)-1b, IL-18, and tumor necrosis factor from
monocytes and Mo-DC (Ferrari et al, 2000; Sluyter et al,
2004a, c), P2X7 on LC may play a pro-inflammatory role in
response to irritant chemicals known to cause ATP release
from keratinocytes (Mizumoto et al, 2002, 2003). It is inter-
esting to speculate on how the pro-inflammatory role for
P2X7 in the skin may be modulated. Water from the Dead
Sea, which is particularly rich in Mg2þ ions, has inhibitory
functions on epidermal LC (Schempp et al, 2000) and since
Mg2þ can reduce the availability of the ATP4 species nec-
essary to activate P2X7 (North, 2002), some of the thera-
peutic properties of treatments using salts from the Dead
Sea may involve inhibition of P2X7. Nevertheless, further
studies to determine the function of P2X7 on epidermal LC
and the role of extracellular ATP in the skin immune system
are warranted.
Materials and Methods
Reagents Nucleotides, RPMI-1640 medium, gentamycin, bovine
serum albumin, DMSO, 7-aminoactinomycin D (7AAD), and et-
hidium bromide were from Sigma Chemica (St Louis, Missouri).
KN-62 was from BIOMOL (Plymouth Meeting, Pennsylvania). Fetal
calf serum, GlutaMAX-1, non-essential amino acids, 2-me-
rcaptoethanol, and 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic
acid (HEPES) were from Invitrogen (Auckland, New Zealand), and
polymerase chain reaction reagents were from Invitrogen (Carls-
bad, California). Ficoll–Paque PLUS was from Amersham Biosci-
ences (Uppsala, Sweden). Dispase II, trypsin, and DNase I were
from Roche Diagnostics (Mannheim, Germany). Granulocyte ma-
crophage colony-stimulating factor (GM-CSF) was a generous gift
from Schering-Plough (Baulkham Hills, Australia). IL-4 and trans-
forming growth factor-b1 (TGFb1) were from R&D Systems (Min-
neapolis, Minnesota). Fluorescein isothiocyanate (FITC)- and
phycoerythrin (PE)-anti-CD1a monoclonal antibodies (mAb),
FITC-conjugated anti-CD80 and anti-CD86 mAb, PE-conjugated
anti-CD11c, anti-CD23, anti-CD39, anti-CD40 and anti-CD83 mAb,
and PerCP-conjugated anti-HLA-DR mAb were from BD Biosci-
ences (San Diego, California). PE-conjugated anti-CD207 (anti-La-
ngerin) mAb was from Beckman-Coulter (Fullerton, California).
Anti-E-cadherin mAb was from Zymed Laboratories (South San
Francisco, California). FITC- and PE-conjugated anti-CD14 mAb
were from Dako (Carpinteria, California). FITC-conjugated anti-
P2X7 receptor was prepared as described (Buell et al, 1998).
Sheep PE-conjugated anti-mouse Ig F(ab0)2 fragment was from
Chemicon (Melbourne, Australia).
Samples Studies were performed according to the Declaration of
Helsinki Principles, and were approved by the Wentworth Area
Health Service Human Ethics Committee (Penrith, Australia). Sam-
ples were collected with informed written consent. Skin (up to
0.5  3 cm) was excised from the abdomen of six patients under-
going routine surgery for various gastrointestinal problems at Ne-
pean Hospital (Penrith, Australia). Peripheral blood (50 mL) was
collected in heparin-containing vacutainer tubes from 16 healthy
subjects of unknown or known P2X7 genotype (Gu et al, 2001,
2004; Wiley et al, 2003; Skarratt et al, 2005).
DNA isolation and P2X7 genotyping Genomic DNA was isolated
from whole blood of subjects with unknown P2X7 genotype using
the Wizard Genomic DNA Purification Kit (Promega Corporation,
Madison, Wisconsin) according to the manufacturer’s instructions.
Exons 1 (including the 50 boundary of intron 1), 9, and 13 of the
P2X7 gene were amplified from genomic DNA by the polymerase
chain reaction and the products were sequenced as described (Gu
et al, 2004).
Isolation of EC EC were isolated as described (Lynch et al, 2003).
Briefly, skin pieces were incubated in RPMI-1640 medium con-
taining 0.5% dispase II and 10 mM HEPES for 18 h at 41C. The
resulting epidermal sheets were incubated in phosphate-buffered
saline (PBS) containing 0.3% trypsin for 20 min at 371C, before
adding an equal volume of RPMI-1640 medium containing 10%
heat-inactivated fetal calf serum, 0.03% DNase I and 10 mM HE-
PES and mechanically agitating for 5 min. The EC suspension was
then filtered through a 70 mm cell strainer, centrifuged, and the EC
were resuspended in NaCl medium (145 mM NaCl, 5 mM KCl, 5 mM
D-glucose, 0.1% bovine serum albumin, 10 mM HEPES, pH 7.5).
Mo-LC and Mo-DC Mo-LC and Mo-DC were generated as pre-
viously described (Geissmann et al, 2002; Sluyter and Wiley, 2002).
Peripheral blood mononuclear cells were separated by gradient
centrifugation using Ficoll–Paque PLUS, and cultured for 2 h at
371C and 95% air/5% CO2 in RPMI-1640 containing 10% heat-
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inactivated fetal calf serum, 2 mM GlutaMAX-1, 0.1 mM non-es-
sential amino acids, 55 mM 2-mercaptoethanol, 5 mg per mL gent-
amycin, and 10 mM HEPES. The plastic-adherent monocytes were
then cultured in complete media (containing 800 U per mL GM-
CSF and 500 U per mL IL-4) in the presence or absence of 10 ng
per mL TGFb1 to generate Mo-LC and Mo-DC, respectively. On
day 3, 50% of the medium was replaced with an equal volume of
complete media containing GM-CSF and either TGFb1 for Mo-LC
or IL-4 for Mo-DC. On day 6, the non-adherent cells were collected
and resuspended in NaCl medium. Flow cytometric analysis of
various molecules on the cell surface of Mo-LC indicated that
72%–99% expressed CD1a, 1%–60% expressed CD207 (La-
ngerin), and 37%–92% expressed E-cadherin. A similar analysis of
the Mo-DC indicated that 65%–99% expressed CD1a, 0%–9%
expressed CD207, and 0%–30% expressed E-cadherin. Additional
details of the Mo-LC and Mo-DC phenotypes can be obtained from
the online supplementary materials (Fig S1, Table S1).
Immunolabeling and ﬂow cytometry Cells were labeled with flu-
orophore-conjugated mAb in NaCl medium containing 10% human
AB serum and 0.01% NaN3, and then washed once with PBS. For
E-cadherin staining, cells were labeled with unconjugated E-cad-
herin or isotype control mAb in NaCl medium containing 10% hu-
man AB serum, 1 mM CaCl2 and 0.01% NaN3, washed twice with
NaCl medium, incubated with sheep PE-conjugated anti-mouse Ig
F(ab0)2 fragment in NaCl medium, and then washed once with PBS.
Cells were examined using a Becton Dickinson (San Jose, Cali-
fornia) FACSCalibur flow cytometer collecting a total of 150–
200  103 events for EC, 5–10  103 events for Mo-LC and Mo-
DC, and 40  103 events for peripheral blood mononuclear cells.
Cells were analyzed in the log mean channel of fluorescence in-
tensity for each gated population using CellQuest Software (Bec-
ton Dickinson). The level of cell surface expression of each
molecule was determined as the MFI of specific mAb binding mi-
nus the MFI of the appropriate isotype control mAb binding.
Measurement of ethidiumþ uptake into epidermal cells EC in 1
mL KCl medium (150 mM KCl, 5 mM D-glucose, 0.1% bovine
serum albumin, 10 mM HEPES, pH 7.5) containing 25 mM et-
hidiumþ were incubated for 5 min at 371C in the presence or ab-
sence of nucleotide as indicated. In some experiments, cells were
pre-incubated for 15 min at 371C in the presence of the P2X7 an-
tagonist, KN-62 (Gargett and Wiley, 1997), or an equal volume of
DMSO vehicle. Incubations with nucleotide were terminated by
adding 1 mL of ice-cold 20 mM MgCl2 medium (20 mM MgCl2, 145
mM NaCl, 5 mM KCl and 10 mM HEPES, pH 7.5) and centrifu-
gation. The cells were then washed with PBS, labeled with FITC-
conjugated anti-CD1a mAb, and the level of ethidiumþ uptake was
determined by flow cytometry. Cells were analyzed in the log mean
channel of fluorescence intensity for each gated population using
CellQuest Software. The level of nucleotide-induced ethidiumþ
uptake was determined as the difference in MFI of cell-associated
ethidiumþ of cells incubated in the presence and absence of nuc-
leotide.
Measurement of ethidiumþ uptake by time-resolved ﬂow
cytometry Nucleotide-induced ethidiumþ influx into Mo-LC, Mo-
DC, and peripheral blood mononuclear cells was measured by
time-resolved flow cytometry as previously described (Sluyter and
Wiley, 2002). Briefly, cells were pre-labeled with FITC-conjugated
anti-CD1a or anti-CD14 mAb and resuspended in 1 mL KCl me-
dium at 371C. At 0 s, 25 mM ethidiumþ was added, followed 40 s
later by the addition of nucleotide as indicated. In some experi-
ments, cells were pre-incubated for 15 min at 371C in the presence
of KN-62 or an equal volume of DMSO vehicle. Data were collected
by flow cytometry over 6 min at 371C with constant stirring using a
Cytek (Fremont, California) Time Zero Module. The linear mean
channel of ethidiumþ fluorescence intensity for each gated pop-
ulation over successive 5 s intervals was analyzed by WinMDI 2.8
Software developed by Joseph Trotter (http://www.scripps.edu)
and plotted against time. Nucleotide-induced ethidiumþ uptake
was quantitated as the difference in arbitrary units of area under
the uptake curves in the presence and absence of nucleotide in the
first 5 min of incubation.
Measurement of CD23 shedding Mo-LC in 1 mL KCl medium
were incubated for 5 min at 371C in the presence or absence of
extracellular nucleotide as indicated. In some experiments, cells
were pre-incubated for 15 min at 371C in the presence of KN-62 or
an equal volume of DMSO vehicle. Incubations with nucleotide
were terminated by adding 1 mL of ice-cold 20 mM MgCl2 medium
and centrifugation. The cells were then washed with PBS, and the
cell surface expression of CD23 was determined using immuno-
labeling and flow cytometry. Results are presented as the per-
centage loss of CD23 expression (MFI) in the presence of
nucleotide compared with CD23 expression (MFI) in the absence
of nucleotide.
Presentation of data and statistics Data are presented as
mean  SD. Comparisons between groups were performed using
the two-tailed Student’s unpaired t test and was considered sig-
nificant when po0.05.
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